EP3620453A1 — New crystal form of lenvatinib
Assigned to Indena SpA · Expires 2020-03-11 · 6y expired
What this patent protects
The present invention provides a novel crystalline form of Lenvatinib mesylate, 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate, a process for its preparation, AND pharmaceutical compositions comprising the novel polymorphic form of …
USPTO Abstract
The present invention provides a novel crystalline form of Lenvatinib mesylate, 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate, a process for its preparation, AND pharmaceutical compositions comprising the novel polymorphic form of Lenvatinib mesylate as active ingredient, in admixture with pharmaceutical excipients.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.